How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

15,009 results for

Systemic Lupus Erythematosus

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

161. Lack of patient education is risk factor of disease flare in patients with systemic lupus erythematosus in China. (PubMed)

Lack of patient education is risk factor of disease flare in patients with systemic lupus erythematosus in China. To explore the inadequacies of health service and its impact on clinical outcomes of patients with systemic lupus erythematosus (SLE) in China.A total of 210 SLE patients were randomly recruited between January 2017 and January 2018. Each patient received self-report questionnaires to assess medication adherence [Compliance Questionnaire for Rheumatology (CQR)], beliefs about (...) with SIMS, EuroQol five-dimensions [EQ5D], Systemic Lupus International Collaborating Clinics (SLICC), depression, use of NSAID (P ≤ 0.05). Remission of disease was positively correlated with SIMS (OR = 0.16, 95% CI: [0.06, 0.40]), and BMQ (OR = 0.64, 95%CI: [0.43, 0.94]).In this study, the scores of BMQ and SIMS were low, implying defects in the patient education of health service system, which led to disease flare in Chinese SLE patients.ClinicalTrials.gov ID: NCT03024307 . Registered January 18, 2017.

2019 BMC health services research

162. A retrospective study of patients with systemic lupus erythematosus combined with Pneumocystis jiroveci pneumonia treated with caspofungin and trimethoprim/sulfamethoxazole. (PubMed)

A retrospective study of patients with systemic lupus erythematosus combined with Pneumocystis jiroveci pneumonia treated with caspofungin and trimethoprim/sulfamethoxazole. Systemic lupus erythematosus (SLE) complicated with Pneumocystis jiroveci pneumonia (PCP) is a clinical complex with unsatisfying treatment efficacy and poor prognosis which is difficult to be diagnosed at early stage. The present study aimed to investigate the clinical features of SLE with PCP, recognize the early onset

2019 Medicine

163. Development and Validation of a microRNA Panel to Differentiate between Patients with Rheumatoid Arthritis or Systemic Lupus Erythematosus and Controls. (PubMed)

Development and Validation of a microRNA Panel to Differentiate between Patients with Rheumatoid Arthritis or Systemic Lupus Erythematosus and Controls. MicroRNAs (miRNAs) are short non-coding RNAs that regulate genes and are both biomarkers and mediators of disease. We used small RNA (sRNA) sequencing and machine learning methodology to develop a miRNA panel to reliably differentiate between rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE) and control subjects.Plasma samples

2019 Journal of Rheumatology

164. Association of Childhood Abuse with Incident Systemic Lupus Erythematosus in Adulthood in a Longitudinal Cohort of Women. (PubMed)

Association of Childhood Abuse with Incident Systemic Lupus Erythematosus in Adulthood in a Longitudinal Cohort of Women. Exposure to severe stressors may alter immune function and augment inflammation and cytokine release, increasing autoimmune disease risk. We examined if childhood abuse was associated with heightened risk of incident systemic lupus erythematosus (SLE).Data were from the Nurses' Health Study II, a cohort of U.S. female nurses enrolled in 1989, followed with biennial

2019 Journal of Rheumatology

165. Blood Pressure Variability and Age-related Blood Pressure Patterns in Systemic Lupus Erythematosus. (PubMed)

Blood Pressure Variability and Age-related Blood Pressure Patterns in Systemic Lupus Erythematosus. Despite the high prevalence of cardiovascular disease among patients with systemic lupus erythematosus, the relationship between age, blood pressure, and blood pressure variability (BPV) is not well understood. We studied visit-to-visit BPV, its relationship to age, clinical, demographic characteristics and its potential role as a cardiovascular risk factor in patients with SLE.We analyzed (...) characteristics, and subsequent cardiovascular events.The mean systolic blood pressure (SBP) in SLE increased with age and was significantly higher in younger patients compared to the general population. BPV in systemic lupus was elevated across all age. BPV was significantly higher in African Americans, in patients with traditional cardiovascular risk factors, those with high disease activity, and in patients taking prednisone. Hydroxychloroquine was associated with significantly lower BPV. Within-person

2019 Journal of Rheumatology

166. T cell receptor β repertoires as novel diagnostic markers for systemic lupus erythematosus and rheumatoid arthritis. (PubMed)

T cell receptor β repertoires as novel diagnostic markers for systemic lupus erythematosus and rheumatoid arthritis. T cell receptor (TCR) diversity determines the autoimmune responses in systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) and is closely associated with autoimmune diseases prognosis and prevention. However, the characteristics of variations in TCR diversity and their clinical significance is still unknown. Large series of patients must be studied in order

2019 Annals of the Rheumatic Diseases

167. A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea. (PubMed)

A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea. Intravenous belimumab plus standard of care (SoC) is approved in the USA and Europe for treatment of active, autoantibody-positive systemic lupus erythematosus (SLE).This phase III, multicentre, randomised, double-blind, placebo-controlled study (BEL113750; NCT01345253) was conducted in 49 centres across China, Japan and South Korea (May (...) 2011-September 2015). Patients with SLE were randomised 2:1 to intravenous belimumab 10 mg/kg or placebo, plus SoC, every 4 weeks until Week 48. The primary endpoint was the SLE Responder Index (SRI) 4 response rate at Week 52. Secondary endpoints were the percentage of patients with ≥4 point reduction in Safety of Oestrogens in Lupus Erythematosus National Assessment-SLE Disease Activity Index (SELENA-SLEDAI), SRI7, time to first severe flare and number of days prednisone (or equivalent) dose ≤7.5

2019 Annals of the Rheumatic Diseases

168. Familial aggregation of childhood and adulthood-onset Systemic Lupus Erythematosus. (PubMed)

Familial aggregation of childhood and adulthood-onset Systemic Lupus Erythematosus. To assess the familial occurrence of systemic lupus erythematosus (SLE) in a large Brazilian cohort.Consecutive SLE patients were recruited, and stratified according to age at disease-onset into childhood (cSLE) or adult (aSLE). Each patient was personally interviewed regarding history of SLE across three generations (first-, second-, and third-degree relatives). Recurrence rates were analyzed for each degree

2019 Arthritis care & research

169. Low Disease Activity State/Remission Predicts a Better Health-Related Quality of Life in Systemic Lupus Erythematosus Patients. (PubMed)

Low Disease Activity State/Remission Predicts a Better Health-Related Quality of Life in Systemic Lupus Erythematosus Patients. To determine if low disease activity state (LDAS)/Remission predicts a better health-related quality of life (HRQoL).Systemic lupus erythematosus (SLE) patients from a single center with at least two visits were included. Visits were performed every six months. HRQoL was measured with the LupusQoL. Remission: a SLEDAI-2K=0, prednisone daily dose≤5mg/d

2019 Arthritis care & research

170. Platelets and IgE: Shaping the Innate Immune Response in Systemic Lupus Erythematosus. (PubMed)

Platelets and IgE: Shaping the Innate Immune Response in Systemic Lupus Erythematosus. Systemic lupus erythematosus (SLE) is a systemic and potentially fatal autoimmune disease. SLE pathophysiology is complex and involves the interplay between the innate and adaptive immune systems, with a particularly significant role for type I interferons. Recently, the participation of other actors such as platelets and IgE has been described in SLE. On the one hand, platelets activated by different stimuli

2019 Clinical Reviews in Allergy & Immunology

171. Relationships Between Adverse Childhood Experiences and Health Status in Systemic Lupus Erythematosus. (PubMed)

Relationships Between Adverse Childhood Experiences and Health Status in Systemic Lupus Erythematosus. Adverse childhood experiences (ACEs) are associated with poor adult health and immune dysregulation. The impact of ACEs on patients with autoimmune disease is unknown. We compared the prevalence of ACEs in Systemic Lupus Erythematosus (SLE) patients to population-based survey estimate and investigated relationships between ACEs and SLE outcomes.Data derive from the California Lupus (...) Epidemiology Study (CLUES), a sample of adult SLE patients. Participants completed a 10-item ACE questionnaire covering 3 domains (abuse, neglect, household challenges). We estimated ACEs prevalence in 269 CLUES participants compared to 2015 California Behavioral Risk Factor Surveillance System (BRFSS) geographically matched respondents, standardized (age, sex, race/ethnicity) to CLUES participant characteristics. We examined associations for patient-reported and physician-assessed health status measures

2019 Arthritis care & research

172. Can we validate a clinical score to predict the risk of severe infection in patients with systemic lupus erythematosus? A longitudinal retrospective study in a British Cohort. (PubMed)

Can we validate a clinical score to predict the risk of severe infection in patients with systemic lupus erythematosus? A longitudinal retrospective study in a British Cohort. Severe infections are a major cause of morbidity and mortality in patients with systemic lupus erythematosus (SLE). Our primary objective was to use data from a large Spanish cohort to develop a risk score for severe infection in SLE, the SLE Severe Infection Score (SLESIS) and to validate SLESIS in a separate cohort

Full Text available with Trip Pro

2019 BMJ open

173. Risk of gestational diabetes mellitus in systemic lupus erythematosus pregnancy: a systematic review and meta-analysis. (PubMed)

Risk of gestational diabetes mellitus in systemic lupus erythematosus pregnancy: a systematic review and meta-analysis. It is well established that the risks of insulin resistance and diabetes mellitus are elevated in systemic lupus erythematosus (SLE) patients. However, the relationship between SLE pregnancy and gestational diabetes mellitus (GDM) is still obscure. We perform the present systematic review and meta-analysis to determine the relationship between GDM and SLE pregnancy.According

Full Text available with Trip Pro

2019 BMC Pregnancy and Childbirth

174. New therapies for systemic lupus erythematosus - past imperfect, future tense. (PubMed)

New therapies for systemic lupus erythematosus - past imperfect, future tense. The failure of many new, mostly biologic, drugs to meet their primary end points in double-blind clinical trials in patients with systemic lupus erythematosus (SLE) has caused a profound sense of disappointment among both physicians and patients. Arguably, the success of B cell depletion with rituximab in open-label clinical trials, the approval of belimumab (which blocks B cell-activating factor (BAFF)) for use (...) in patients with lupus nephritis in the USA and in difficult-to-treat patients with SLE in the UK and the recognition that clinical trial design can be improved have given some cause for hope. However, changes to therapies in current use and the development of new approaches are urgently needed. The results of the latest studies investigating the use of several new approaches to treating SLE are discussed in this Review, including: fully humanized anti-CD20 and anti-CD19 monoclonal antibodies; inhibition

2019 Nature reviews. Rheumatology

175. Association of Epstein-Barr virus serological reactivation with transitioning to systemic lupus erythematosus in at-risk individuals. (PubMed)

Association of Epstein-Barr virus serological reactivation with transitioning to systemic lupus erythematosus in at-risk individuals. Systemic lupus erythematosus (SLE) is a systemic autoimmune disease with unknown aetiology. Epstein-Barr virus (EBV) is an environmental factor associated with SLE. EBV maintains latency in B cells with frequent reactivation measured by antibodies against viral capsid antigen (VCA) and early antigen (EA). In this study, we determined whether EBV reactivation

2019 Annals of the Rheumatic Diseases

176. Non-scarring alopecia in systemic lupus erythematosus: a cross-sectional study with trichoscopic, histopathological and immunopathological analyses. (PubMed)

Non-scarring alopecia in systemic lupus erythematosus: a cross-sectional study with trichoscopic, histopathological and immunopathological analyses. Non-scarring alopecia in systemic lupus erythematosus (SLE) is widely recognized but reports on its clinical, trichoscopic, histopathological and direct immunofluorescence (DIF) features are still limited.To summarize the different clinical patterns, trichoscopic, histopathological and DIF features of non-scarring alopecia in SLE, as well (...) as proving its association with disease activity.SLE patients with and without non-scarring alopecia underwent full physical/trichoscopic examination and scalp biopsy. Their disease activity scores and laboratory data were evaluated and statistically analyzed.Thirty-two SLE patients had different patterns of non-scarring alopecia including: mild diffuse alopecia, severe diffuse alopecia, patchy alopecia and lupus hair. The most common trichoscopic findings were arborizing/interconnecting vessels (81.3

Full Text available with Trip Pro

2019 Journal of American Academy of Dermatology

177. Longitudinal disease- and steroid-related damage among adults with childhood-onset systemic lupus erythematosus. (PubMed)

Longitudinal disease- and steroid-related damage among adults with childhood-onset systemic lupus erythematosus. Determine whether adults with childhood-onset systemic lupus erythematosus (cSLE) are at increased risk for disease- and steroid-related damage as compared to individuals with adult-onset SLE (aSLE), and whether they continue to accumulate disease damage in adulthood.Data derive from the 2007-2015 cycles of the Lupus Outcomes Study, a longitudinal cohort of adults with confirmed SLE (...) . The Brief Index of Lupus Damage (BILD), a validated, patient-reported measure, was used to assess SLE-associated damage. Participants with baseline BILD were included (N = 1035). Diagnosis at age < 18 years was defined as cSLE (N = 113). Outcome variables included BILD score at baseline and follow-up, clinically significant change in BILD score over follow-up period, and presence of steroid-related damage (cataracts, osteoporosis-related fracture, avascular necrosis or diabetes mellitus).Mean time

2019 Seminars in arthritis and rheumatism

178. Libman-Sacks Endocarditis Involving a Bioprosthesis in the Aortic Valve Position in Systemic Lupus Erythematosus. (PubMed)

Libman-Sacks Endocarditis Involving a Bioprosthesis in the Aortic Valve Position in Systemic Lupus Erythematosus. Described herein is a 39-year-old man with systemic lupus erythematosus not receiving corticosteroid therapy who developed Libman-Sacks endocarditis causing stenosis of a bioprosthesis in the aortic valve position.Copyright © 2019 Elsevier Inc. All rights reserved.

2019 American Journal of Cardiology

179. Abnormal Cardiac Biomarkers in Patients with Systemic Lupus Erythematosus and No Prior Heart Disease: The Role of Endomyocardial Biopsy. (PubMed)

Abnormal Cardiac Biomarkers in Patients with Systemic Lupus Erythematosus and No Prior Heart Disease: The Role of Endomyocardial Biopsy. Tselios, et al reported in their recent study that patients with systemic lupus erythematosus (SLE) who receive prolonged antimalarial (AM) treatment are at increased risk for elevated cardiac biomarkers [brain natriuretic peptide (BNP) and high-sensitivity cardiac troponin I (HS-cTnI)], particularly when persistently elevated creatine phosphokinase (CPK

2019 Journal of Rheumatology

180. Risk factors for progression of carotid intima-media thickness in patients with systemic lupus erythematosus: protocol for an observational cohort study in China. (PubMed)

Risk factors for progression of carotid intima-media thickness in patients with systemic lupus erythematosus: protocol for an observational cohort study in China. Accelerated atherosclerosis is a major complication of systemic lupus erythematosus (SLE), and it leads to increased cardiovascular morbidity and mortality in patients with SLE. This study aimed to investigate the natural progression of carotid intima-media thickness (CIMT), and to examine the risk factors for progression of CIMT

2019 BMJ open

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>